¼¼°èÀÇ ¿¬±¸¿ë Ç×ü ½ÃÀå
Research Antibodies
»óǰÄÚµå : 1594995
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 93 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,260,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,780,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¿¬±¸¿ë Ç×ü ½ÃÀåÀº 2030³â±îÁö 58¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 42¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¿¬±¸¿ë Ç×ü ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2023-2030³â¿¡ CAGR 4.9%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 58¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ½Ã¾àÀº CAGR 4.6%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 48¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç×ü ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 6.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 12¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 4.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ¿¬±¸¿ë Ç×ü ½ÃÀåÀº 2023³â¿¡ 12¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2023-2030³â CAGR 4.6%¸¦ °ßÀÎÇϸç 2030³â±îÁö 10¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 4.3%¿Í 4.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¿¬±¸¿ë Ç×ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°úÇÐÀû ¹ß°ß¿¡ ÇʼöÀûÀÎ ¿¬±¸¿ë Ç×ü¶õ?

¿¬±¸¿ë Ç×ü´Â ƯÁ¤ ´Ü¹éÁú¿¡ Á¤È®ÇÏ°Ô °áÇÕÇÏ´Â ´É·ÂÀ» ÅëÇØ °úÇÐÀÚµéÀÌ º¹ÀâÇÑ »ý¹°ÇÐÀû »ùÇÿ¡¼­ »ýü ºÐÀÚ¸¦ °ËÃâ, ÃøÁ¤ ¹× Á¶ÀÛÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â »ý¹°ÇÐ ¿¬±¸¿¡ ÇʼöÀûÀÎ ÅøÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ç×ü´Â ºÐÀÚ»ý¹°ÇÐ, ¸é¿ªÇÐ, Á¾¾çÇÐ, ½Å°æ°úÇÐ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ ¼¼Æ÷ °úÁ¤, ½ÅÈ£ Àü´Þ °æ·Î ¹× Áúº´ ¸ÞÄ¿´ÏÁòÀ» Á¶»çÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Ç×ü´Â ¿þ½ºÅÏ ºí·ÎÆÃ, ¸é¿ªÁ¶Á÷È­ÇÐ(IHC), È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø¹ý(ELISA) µîÀÇ ¹æ¹ýÀ¸·Î Á¶Á÷ ¹× ¼¼Æ÷³» ´Ü¹éÁú ¹× ±âŸ Ç׿øÀ» ½Äº°ÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ Æ¯À̼º°ú ¹ü¿ë¼ºÀ¸·Î ÀÎÇØ ¿¬±¸¿ë Ç×ü´Â ±âÃÊ »ý¹°ÇÐ ¹× Áúº´ º´¸®ÇÐÀ» ÀÌÇØÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

Á¤¹ÐÀÇ·á¿Í ¸ÂÃã Ä¡·áÀÇ ½Ã´ë¿¡ ºÐÀÚ ¼öÁØ¿¡¼­ Ç¥Àû ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÏ´Â ¿¬±¸¿ë Ç×ü´Â ´õ¿í Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¾Ï ¿¬±¸¿¡¼­ Ç×ü´Â Ä¡·á ¹æÄ§À» °áÁ¤Çϰí Áúº´ÀÇ ÁøÇàÀ» ¸ð´ÏÅ͸µÇϱâ À§ÇÑ ¹ÙÀÌ¿À¸¶Ä¿¸¦ °ËÃâÇÏ´Â µ¥ ÀÚÁÖ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ »ó¼¼ÇÑ ºÐÀÚ ÇÁ·ÎÆÄÀϸµÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ¿¬±¸¿ë Ç×ü´Â ±âÃʰúÇаú ÀÓ»ó Àû¿ëÀ» ¸ðµÎ Áö¿øÇÕ´Ï´Ù. Áø´Ü ¹× Ä¡·á ÀÇ»ç°áÁ¤¿¡ ÀÖÀ¸¸ç, ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Á߿伺ÀÌ ³ô¾ÆÁü¿¡ µû¶ó °íǰÁúÀÇ ½Å·ÚÇÒ ¼ö ÀÖ´Â Ç×ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ¿¬±¸¿ë Ç×ü´Â °úÇÐÀû Áö½ÄÀ» ½ÉÈ­½Ãų »Ó¸¸ ¾Æ´Ï¶ó, Áß°³ ¿¬±¸ ¹× ÀÓ»ó ¿¬±¸ Àû¿ëÀ» ÅëÇØ ȯÀÚ Ä¡·á °á°ú¸¦ °³¼±ÇÏ´Â µ¥ ÇʼöÀûÀÎ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¾î¶»°Ô ¿¬±¸¿ë Ç×ü ½ÃÀåÀ» Çü¼ºÇϰí Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ¿¬±¸¿ë Ç×üÀÇ ´É·Â°ú ¿ëµµ¸¦ Å©°Ô È®ÀåÇÏ¿© º¸´Ù ƯÀÌÀûÀÌ°í ¾ÈÁ¤ÀûÀ̸ç ÀçÇö¼ºÀÌ ³ôÀº Ç×ü¸¦ °³¹ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÁÖ¿ä ±â¼ú Çõ½Å Áß Çϳª´Â À¯ÀüÀÚ º¹Á¦ ¹× ¹ßÇö ±â¼úÀ» »ç¿ëÇÏ¿© »ý»êµÇ´Â ÀçÁ¶ÇÕ Ç×üÀÇ °³¹ßÀÔ´Ï´Ù. ÀçÁ¶ÇÕ Ç×ü´Â ±âÁ¸ÀÇ ´ÜÀÏ Å¬·Ð Ç×ü¿Í ´Þ¸® Àϰü¼ºÀÌ ³ô°í ¹èÄ¡ °£ ÆíÂ÷°¡ ¾ø¾î ½ÇÇèÀû ¿¬±¸¿¡¼­ ½Å·Ú¼ºÀÌ ³ô½À´Ï´Ù. ÀÌ·¯ÇÑ Àϰü¼ºÀº Á¤È®ÇÑ ºÐ¼®À» À§ÇØ ÀçÇö¼ºÀÌ ÇʼöÀûÀÎ ÀÓ»ó ¹× Á¦¾à ¿ëµµ¿¡¼­ ƯÈ÷ °¡Ä¡°¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀçÁ¶ÇÕ Ç×ü´Â Ç¥Àû Ç׿ø¿¡ ´ëÇØ ´õ ³ôÀº ƯÀ̼º°ú Ä£¹Ðµµ¸¦ °®µµ·Ï ¼³°èÇÒ ¼ö ÀÖÀ¸¹Ç·Î Ç¥Àû ¿Ü È¿°úÀÇ °¡´É¼ºÀ» ³·Ãß°í ½ÇÇè °á°úÀÇ Á¤È®¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ ±â¼úÀû Áøº¸´Â ³«Å¸°ú Ç×ü¿¡¼­ À¯·¡ÇÑ ´ÜÀÏ µµ¸ÞÀÎ Ç×ü, Áï '³ª³ë Ç×ü'ÀÇ ÃâÇöÀÔ´Ï´Ù. ÀÌ ³ª³ëü´Â ±âÁ¸ Ç×üº¸´Ù ÀÛ°í ¾ÈÁ¤¼ºÀÌ ³ô¾Æ »ý¼¼Æ÷ À̹Ì¡À̳ª ¼¼Æ÷³» ¿¬±¸¿Í °°ÀÌ ±âÁ¸ Ç×ü°¡ ³Ê¹« Å©°Å³ª ºÒ¾ÈÁ¤ÇÑ ¿ëµµ¿¡ ÀûÇÕÇÕ´Ï´Ù. ³ª³ëü´Â ¼¼Æ÷³» Ç¥Àû¿¡ Á¢±ÙÇÏ°í °áÇÕÇÒ ¼ö ÀÖÀ¸¸ç, ´Ü¹éÁú »óÈ£ÀÛ¿ëÀ» ½Ç½Ã°£À¸·Î ¿¬±¸ÇÒ ¼ö ÀÖ´Â »õ·Î¿î °¡´É¼ºÀ» ¿­¾îÁÝ´Ï´Ù. ¶ÇÇÑ ÀÚµ¿È­ ¹× °íó¸® ½ºÅ©¸®´× ±â¼úÀº Ç×ü °³¹ß °úÁ¤À» ´õ ºü¸£°í È¿À²ÀûÀ¸·Î ¸¸µé¾î ¿¬±¸ÀÚµéÀÌ ´ë·®ÀÇ Ç×ü ¶óÀ̺귯¸®¸¦ ½ºÅ©¸®´×ÇÏ¿© °¡Àå È¿°úÀûÀÎ È常¦ ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº °úÇÐÀڵ鿡°Ô ÁøÈ­ÇÏ´Â Çö´ëÀÇ ¿¬±¸ ¿ä±¸¿¡ ºÎÇÕÇÏ´Â ´Ù¾çÇÑ ÅøÀ» Á¦°øÇÔÀ¸·Î½á ¿¬±¸¿ë Ç×ü ½ÃÀåÀ» ÀçÆíÇϰí ÀÖ½À´Ï´Ù.

¿¬±¸¿ë Ç×ü ½ÃÀå¿¡ Á¸ÀçÇÏ´Â °úÁ¦¿Í ±âȸ´Â?

¿¬±¸¿ë Ç×ü´Â °úÇÐÀû ¹ß°ß¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÏÁö¸¸, ½ÃÀå¿¡¼­´Â Á¦Ç°ÀÇ Ç°Áú°ú ÀçÇö¼º¿¡ ´ëÇÑ Å« ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. °¡Àå Å« ¹®Á¦ Áß Çϳª´Â ½ÃÁß¿¡¼­ ÆÇ¸ÅµÇ´Â ¸ðµç Ç×ü°¡ ƯÀ̼º°ú Àϰü¼º Ãø¸é¿¡¼­ ¿ä±¸µÇ´Â ±âÁØÀ» ÃæÁ·ÇÏÁö ¸øÇÑ´Ù´Â Á¡ÀÔ´Ï´Ù. ¹èÄ¡ °£ ÆíÂ÷ ¹× ºÒÃæºÐÇÑ °ËÁõÀº ½Å·ÚÇÒ ¼ö ¾ø´Â ½ÇÇè °á°ú¸¦ ÃÊ·¡ÇÏ´Â ÀϹÝÀûÀÎ ¹®Á¦À̸ç, ÀÌ´Â ±Ã±ØÀûÀ¸·Î ¿¬±¸ °á°úÀÇ ½Å·Ú¼º¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¶ÇÇÑ ºñƯÀÌÀû °áÇÕ ¹× ±³Â÷ ¹ÝÀÀ¼ºÀÌ Á¸ÀçÇϸé À§¾ç¼º ¹× À§À½¼ºÀÌ ¹ß»ýÇÏ¿© µ¥ÀÌÅÍ ºÐ¼®ÀÌ º¹ÀâÇØÁý´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÏ°í °úÇÐ ¿¬±¸ÀÇ ÀçÇö¼ºÀ» º¸ÀåÇϱâ À§ÇØ Ç¥ÁØÈ­µÈ °ËÁõ ÇÁ·ÎÅäÄݰú Ç×ü ¼º´É¿¡ ´ëÇÑ Åõ¸íÇÑ µ¥ÀÌÅ͸¦ ¿ä±¸ÇÏ´Â ¿¬±¸ÀÚ ¹× ¿¬±¸ ±â°üÀÇ ¸ñ¼Ò¸®°¡ Á¡Á¡ ´õ Ä¿Áö°í ÀÖ½À´Ï´Ù.

±×·¯³ª ÀÌ·¯ÇÑ µµÀüÀº ½ÃÀå ¼ºÀå°ú Çõ½ÅÀÇ ±âȸ·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÇöÀç °¢ ±â¾÷Àº ¿¬±¸Àڵ鿡°Ô Á¦Ç°ÀÇ ½Å·Ú¼ºÀ» º¸ÀåÇϱâ À§ÇØ µ¶¸³ÀûÀÎ Á¦3ÀÚ Å×½ºÆ®¸¦ Æ÷ÇÔÇÑ ¾ö°ÝÇÑ Ç°Áú°ü¸® ¹× °ËÁõ ÇÁ·Î¼¼½º¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æ¯Á¤ ¿¬±¸ ¿ä±¸¿¡ ¸Â´Â ¸ÂÃãÇü Ç×ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü Ç×ü ¼­ºñ½º´Â Á¾Á¾ ÀçÁ¶ÇÕ ±â¼úÀ» ÅëÇØ ¿¬±¸ÀÚ °íÀ¯ÀÇ Ç¥Àû°ú ¿ëµµ¿¡ ÃÖÀûÈ­µÈ Ç×ü¸¦ Á¦°øÇÕ´Ï´Ù. ¿¬±¸ÀÚµéÀÌ Ç×üÀÇ ³ôÀº ¼öÁذú ¸ÂÃãÈ­¸¦ ¿ä±¸ÇÔ¿¡ µû¶ó ½ÃÀåÀº º¸´Ù Àü¹®ÀûÀÎ Á¦°ø°ú °ËÁõÀ» °­È­ÇÏ´Â ¹æÇâÀ¸·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´õ ¸¹Àº Çмú±â°ü°ú ¿¬±¸ Áö¿ø ±â°üÀÌ ÀçÇö¼ºÀ» Áß¿ä½ÃÇÏ´Â °¡¿îµ¥, °ËÁõµÇ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Ç×ü¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â ±â¾÷Àº °æÀï ¿ìÀ§¸¦ È®º¸ÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ ¾ò°Ô µÉ °ÍÀÔ´Ï´Ù.

¿¬±¸¿ë Ç×ü ½ÃÀåÀ» °¡¼ÓÈ­ÇÏ´Â ÁÖ¿ä ÃËÁø¿äÀÎÀº?

¿¬±¸¿ë Ç×ü ½ÃÀåÀÇ ¼ºÀåÀº »ý¹° ÀÇÇÐ ¿¬±¸ÀÇ ¹ßÀü°ú °íǰÁú ¿¬±¸ Åø¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ ¹Ý¿µÇÏ´Â ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, °¨¿°¼º Áúȯ°ú °°Àº Áúº´ Áõ°¡´Â ÁÖ¿ä ÃËÁø¿äÀÎ Áß ÇϳªÀ̸ç, ¿¬±¸ÀÚµéÀº Áúº´ °æ·Î¸¦ ¿¬±¸Çϰí, ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°Çϰí, ÀáÀçÀû Ä¡·á Ç¥ÀûÀ» °³¹ßÇϱâ À§ÇØ Ç×ü¸¦ ã°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¾Ï ¿¬±¸¿¡¼­ Ç×ü´Â Á¾¾çÀÇ °Åµ¿À» ÀÌÇØÇϰí, ¿¹Èĸ¦ Æò°¡Çϰí, ¸ÂÃãÇü Ä¡·á¸¦ ¼³°èÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ƯÁ¤ ´Ü¹éÁú ¸¶Ä¿¸¦ ½Äº°ÇÏ´Â µ¥ ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¾à¹°ÀÇ È¿´ÉÀ» Å×½ºÆ®Çϰí ÀáÀçÀûÀΠǥÀû ¿Ü È¿°ú¸¦ ¸ð´ÏÅ͸µÇÏ´Â µ¥ »ç¿ëµÇ´Â ¾à¹° °³¹ß¿¡¼­ÀÇ Ç×ü »ç¿ë È®´ëµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ Çаè, Á¦¾à»ç, Á¤ºÎ ±â°üÀÇ ¿¬±¸°³¹ß ÅõÀÚ È®´ë°¡ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á¹ý°ú Áø´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó »ý¹° ÀÇÇÐ ¿¬±¸ ÀÚ±ÝÀÌ Áõ°¡ÇÏ¿© ¿¬±¸¿ë Ç×ü ½ÃÀåÀÌ °ß°íÇÏ°Ô Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½Å¾à °³¹ß¿¡¼­ ÇÏÀ̽º·çDz ½ºÅ©¸®´× ±â¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´ë±Ô¸ð ¿¬±¸¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â Ç×ü¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ µîÀÇ ºÐ¾ß°¡ ¹ßÀüÇÔ¿¡ µû¶ó ´Ù¾çÇÑ ´Ü¹éÁúÀ» Ç¥ÀûÀ¸·Î »ï°í »ó¼¼ÇÑ ºÐÀÚ ºÐ¼®ÀÌ °¡´ÉÇÑ Ç×ü¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ƯÈ÷ ºÏ¹Ì¿Í À¯·´°ú °°Àº Áö¿ª¿¡¼­´Â Á¤ºÎ Â÷¿øÀÇ »ýÀÇÇÐ ¿¬±¸ Áö¿ø Á¤Ã¥ÀÌ ½ÃÀåÀ» °­È­Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ ¼ºÀå°ú ±â¼ú Çõ½Å¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(½Ã¾à, Ç×ü), ±â¼ú(¿þ½ºÅÏ ºí·ÎÆÃ, À¯¼¼Æ÷ºÐ¼®, È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø ÃøÁ¤¹ý(ELISA), ¸é¿ªÁ¶Á÷È­ÇÐ, ¸é¿ª Çü±¤, ¸é¿ª ħ°­, ±âŸ ±â¼ú), ¿ëµµ(Á¾¾çÇÐ, °¨¿°Áõ, ¸é¿ªÇÐ, Áٱ⼼Æ÷, ½Å°æ »ý¹°ÇÐ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, Çмú¡¤¿¬±¸±â°ü, CRO(ÀÓ»ó½ÃÇè ¼öʱâ°ü ±â°ü)).

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 42°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Research Antibodies Market to Reach US$5.8 Billion by 2030

The global market for Research Antibodies estimated at US$4.2 Billion in the year 2023, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Reagent, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Antibodies segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 4.6% CAGR

The Research Antibodies market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 4.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Research Antibodies Market - Key Trends & Drivers Summarized

What Makes Research Antibodies Vital in Scientific Discovery?

Research antibodies are essential tools in biological research, utilized for their ability to precisely bind to specific proteins, allowing scientists to detect, measure, and manipulate biomolecules within complex biological samples. These antibodies play a critical role across various fields, including molecular biology, immunology, oncology, and neuroscience, as they enable researchers to investigate cellular processes, signaling pathways, and disease mechanisms. Antibodies are used in techniques such as Western blotting, immunohistochemistry (IHC), and enzyme-linked immunosorbent assay (ELISA), among others, to identify proteins or other antigens in tissues and cells. Their specificity and versatility make research antibodies indispensable for advancing our understanding of fundamental biology and disease pathology.

In the era of precision medicine and personalized therapies, research antibodies have become even more crucial as they allow for targeted analysis at the molecular level. For instance, in cancer research, antibodies are frequently used to detect biomarkers that inform treatment decisions and monitor disease progression. By enabling such detailed molecular profiling, research antibodies support both basic science and clinical applications. With the growing importance of biomarkers in diagnostics and therapeutic decision-making, the demand for high-quality, reliable antibodies is on the rise. This makes research antibodies essential tools not only for advancing scientific knowledge but also for improving patient outcomes through their application in translational and clinical research.

How Are Technological Innovations Shaping the Research Antibodies Market?

Technological advancements have greatly expanded the capabilities and applications of research antibodies, leading to the development of more specific, stable, and reproducible antibodies. One of the major innovations is the development of recombinant antibodies, which are produced using gene cloning and expression techniques. Unlike traditional monoclonal antibodies, recombinant antibodies offer higher consistency and are not subject to batch-to-batch variability, making them more reliable for experimental research. This consistency is particularly valuable in clinical and pharmaceutical applications, where reproducibility is essential for accurate analysis. Additionally, recombinant antibodies can be engineered to have higher specificity and affinity for target antigens, reducing the likelihood of off-target effects and improving the accuracy of experimental results.

Another significant technological advancement is the emergence of single-domain antibodies, or "nanobodies," derived from camelid antibodies. These nanobodies are smaller and more stable than traditional antibodies, making them ideal for applications where traditional antibodies may be too large or unstable, such as in live-cell imaging and intracellular studies. Nanobodies have the potential to access and bind to targets within cells, opening new possibilities for studying protein interactions in real time. Furthermore, automation and high-throughput screening technologies are enabling faster and more efficient antibody development processes, allowing researchers to screen large libraries of antibodies to identify the most effective candidates. These innovations are reshaping the research antibodies market by providing scientists with a wider range of tools tailored to the evolving needs of modern research.

What Challenges and Opportunities Exist in the Research Antibodies Market?

While research antibodies are invaluable to scientific discovery, the market faces significant challenges related to product quality and reproducibility. One of the primary concerns is that not all commercially available antibodies meet the required standards for specificity and consistency. Batch-to-batch variability and inadequate validation are common issues that can lead to unreliable experimental results, ultimately impacting the credibility of research findings. Furthermore, the presence of non-specific binding or cross-reactivity can produce false positives or negatives, complicating data interpretation. Researchers and institutions increasingly call for standardized validation protocols and transparent data on antibody performance to address these issues and ensure reproducibility in scientific research.

However, these challenges have also spurred opportunities for growth and innovation in the market. Companies are now investing in rigorous quality control and validation processes, including independent third-party testing, to assure researchers of the reliability of their products. Additionally, there is an increasing demand for customized antibody solutions tailored to specific research needs. Custom antibody services provide researchers with antibodies that are optimized for their unique targets and applications, often through recombinant techniques. As researchers seek higher standards and customization in antibodies, the market is shifting toward more specialized offerings and enhanced validation. Furthermore, as more academic institutions and research funding bodies emphasize reproducibility, companies that can deliver well-validated and reliable antibodies are poised to gain a competitive advantage.

What Are the Key Drivers Accelerating the Research Antibodies Market?

The growth in the research antibodies market is driven by several factors, reflecting advancements in biomedical research and the rising demand for high-quality research tools. The increasing prevalence of diseases such as cancer, autoimmune disorders, and infectious diseases is one of the primary drivers, as researchers seek antibodies to study disease pathways, identify biomarkers, and develop potential therapeutic targets. In cancer research, for example, antibodies are used extensively to identify specific protein markers that help researchers understand tumor behavior, assess prognosis, and design personalized treatments. The expanding application of antibodies in drug development, where they are used to test drug efficacy and monitor potential off-target effects, is also driving market growth.

Another key driver is the growing investment in research and development by academic institutions, pharmaceutical companies, and government agencies. As the demand for new therapies and diagnostic tools rises, funding for biomedical research has increased, creating a robust market for research antibodies. Additionally, the increasing adoption of high-throughput screening techniques in drug discovery is further boosting the demand for reliable antibodies that can be used in large-scale studies. With advances in fields like genomics and proteomics, there is also a rising need for antibodies that can target a broad range of proteins, enabling detailed molecular analysis. Finally, government policies that support biomedical research, particularly in regions like North America and Europe, have strengthened the market, helping to ensure sustained growth and innovation in the research antibodies sector.

SCOPE OF STUDY:

The report analyzes the Research Antibodies market in terms of US$ Million by the following Application; End-Use; Product; Technology, and Geographic Regions/Countries:

Segments:

Product (Reagent, Antibodies); Technology (Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation, Other Technologies); Application (Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology, Other Applications); End-Use (Pharma & Biotech Companies, Academic & Research Institutions, Contract Research Organizations (CROs))

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â